The deal comes a little more than month after the companies agreed to form a joint venture that will develop a blockchain-based healthcare service platform.
The system is designed to provide a quantitative determination of red blood cells and total nucleated cells in CSF.
The lab will make Lucence's non-invasive cancer tests available to patients in the region, but financial and other terms were not disclosed.
The company will supply the Chinese laboratory with its ClearCell FX1 system and help train and assist its new partner in developing cancer tests.
The company's assay, performed on FFPE tissue, measures the density of two T lymphocyte populations to help physicians assess disease prognosis.
The agreement extends the reach of Biocept's Target Selector testing to a large new region and brings its total reach to 17 countries outside the US.
The deal covers MNG's complete line of neurogenetic clinical RNA sequencing services, including complete transcriptome sequencing.
The deal begins commercialization of Emosis' first test for heparin-induced thrombocytopenia in at least 36 countries that recognize CE marking.
Owen Mumford has acquired the exclusive rights to Atomo's CE-marked HIV tests and will bring them to market in Europe under the Simplitude brand.
The companion diagnostic test identifies patients taking the Novartis drug Tasigna who are candidates for treatment-free remission monitoring.